WO2025202971 - KRAS G12C INHIBITOR FOR USE FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
National phase entry is expected:
Publication Number
WO/2025/202971
Publication Date
02.10.2025
International Application No.
PCT/IB2025/053263
International Filing Date
27.03.2025
Title **
[English]
KRAS G12C INHIBITOR FOR USE FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
[French]
INHIBITEUR DE KRAS G12C DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DU CANCER DU POUMON NON À PETITES CELLULES
Applicants **
NOVARTIS AG
Lichtstrasse 35
4056 Basel, CH
Inventors
BITTON, Rafael Caparica
Novartis Pharma AG
Lichtstrasse 35
4056 Basel, CH
CUI, Xiaoming
Novartis Pharmaceuticals Corporation
59 Route 10
East Hanover, New Jersey 07936, US
LOBETTI BODONI, Chiara
Novartis Pharma AG
Lichtstrasse 35
4056 Basel, CH
YOVINE, Alejandro Javier
Novartis Pharma AG
Lichtstrasse 35
4056 Basel, CH
Priority Data
63/570,545
27.03.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1392 | |
| EPO | Filing, Examination | 7364 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 3910 |
Total: 13828 USD
Abstract[English]
The present invention relates to a method of treating non-small cell lung cancer (NSCLC) which harbors a KRAS G12C mutation, wherein the method comprises the administration of KRAS G12C inhibitor 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one (Compound A), or a pharmaceutically acceptable salt, solvate or hydrate thereof, and a therapeutically effective amount of pembrolizumab; in particular the present invention relates to a method of treating NSCLC wherein the NSCLC expresses at least 1% PD-L1 according to the tumor proportion score (TPS), more particularly the NSCLC expresses at least 50% PD-L1 according to the tumor proportion score (TPS).[French]
La présente invention concerne une méthode de traitement du cancer du poumon non à petites cellules (NSCLC) qui héberge une mutation KRAS G12C. La méthode consiste à administrer un inhibiteur de KRAS G12C, 1-6-[(4M)-4-(5-chloro-6-méthyl-1H-indazol-4-yl)-5-méthyl-3-(1-méthyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3,3]heptan-2-yl}prop-2-en-1-one (composé A), ou un sel, solvate ou hydrate pharmaceutiquement acceptable de celui-ci, et une quantité thérapeutiquement efficace de pembrolizumab. En particulier, la présente invention concerne une méthode de traitement du NSCLC, le NSCLC exprimant au moins 1 % de PD-L1 selon le score de proportion tumorale (TPS), plus particulièrement le NSCLC exprimant au moins 50 % de PD-L1 selon le score de proportion tumorale (TPS).